Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H24F3N5O3.C7H8O3S |
Molecular Weight | 743.751 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)S(O)(=O)=O.CC(C)OC2=CC=C(C=C2F)C3=NN([C@@H](C)C4=C(C5=CC(F)=CC=C5)C(=O)C6=C(O4)C=CC(F)=C6)C7=C3C(N)=NC=N7
InChI
InChIKey=KYJWUPZPSXZEPG-NTISSMGPSA-N
InChI=1S/C31H24F3N5O3.C7H8O3S/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29;1-6-2-4-7(5-3-6)11(8,9)10/h4-16H,1-3H3,(H2,35,36,37);2-5H,1H3,(H,8,9,10)/t16-;/m0./s1
Umbralisib (TGR-1202) is an orally available PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of PI3K. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-cell lymphocytes. Inhibition of PI3K delta signaling with umbralisib has demonstrated robust activity in numerous pre-clinical models and primary cells from patients with hematologic malignancies. Umbralisib is currently in Phase 3 clinical development in combination with Ublituximab for patients with hematologic malignancies.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27784673 |
22.2 nM [EC50] | ||
Target ID: P49674 Gene ID: 102800317|||1454 Gene Symbol: CSNK1E Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27784673 |
|||
Target ID: O00329 Gene ID: 5293.0 Gene Symbol: PIK3CD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29475723 |
6.2 nM [Kd] | ||
Target ID: P49674 Gene ID: 102800317|||1454 Gene Symbol: CSNK1E Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29475723 |
180.0 nM [Kd] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30558987
relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: umbralisib orally once daily (400 mg, 600 mg, or 800 mg) and ibrutinib orally once daily (420 mg for chronic lymphocytic leukaemia or 560 mg for mantle cell lymphoma) until disease progression or unacceptable toxicity. Umbralisib plus ibrutinib is well tolerated and active in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma, with a recommended phase 2 dose of umbralisib 800 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.tgtxinc.com/AACR2012Poster3741.pdf
Umbralisib (TGR-1202), a novel, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 & 24.3 nM, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
||
|
NCI_THESAURUS |
C2152
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CD-145
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
1532533-72-4
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545267
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
86707828
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
FU8XW5V3FS
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
300000013063
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
FU8XW5V3FS
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
2478438
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
C152795
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD